Stifel analyst Stephen Willey noted that following the White House Coronavirus Task Force meeting in Washington D.C., there was an announcement of the acceleration of development timelines for Inovio's COVID-19 DNA vaccine candidate INO-4800, with human trials now set to begin next month. He also noted the newly-issued guidance suggesting 1M doses will be available by year-end 2020. The analyst, who believes Inovio's ongoing clinical development of a MERS-targeting vaccine provides leverageable experience and thinks the company's nucleic acid-based vaccine technology gives it meaningful advantages on the manufacturing/production fronts, has a Buy rating and $7 price target on Inovio shares. However, he "admittedly [has] no visibility into the pathway to longer-term value creation here," the analyst added.